Ekkio Capital has signed an exclusive agreement with Eurofins for the sale of Amatsigroup
Paris, July 10th, 2017 – Ekkio Capital, a sector-based investor dedicated to high-potential European SMEs, announces that it has signed an exclusive agreement with Eurofins (EUFI.PA), a global leader in bio-pharmaceutical products testing, and one of the world leaders in genomic services, for the sale of Amatsigroup. The company is a leading international contract development and manufacturing organization (CDMO) providing preclinical and clinical services for the development of human and veterinary drugs.
Founded in 2010 by Ekkio Capital, Amatsigroup was formed through the merger of four companies (Avogadro, Amatsi, DBI and Avepharm) and has grown though several strategic acquisitions: SEPS Pharma (Belgium), Amatsigroup Inc. (USA) in 2014, Pierre Fabre’s pharmaceutical analysis laboratory in 2015, QBiologicals (Belgium) in 2016, Disposable Lab early 2017 and more recently two sites of Bertin Pharma.
Over the past 6 years, Amatsigroup became one of the largest independent multispecialist platform in Europe with a unique proposal for specialty and biopharma clients, including pharmaceutical analysis, formulation development and manufacturing, biological research & development, among other services. The company has about 450 employees over 8 sites in France, 2 sites in Belgium and 1 site in the USA.
Given its unique positioning as a high value added multi-specialist drug development services provider, the company is well-positioned to leverage and strengthen its footprint in the CDMO industry.
The contemplated transaction is expected to be completed over the next few months, subject to customary closing conditions including employees’ representatives’ information and consultation.
Councels of the operation :
- Operation : Rothschild – F. de BRETEUIL / R. ROZEMULDER / E. GIORNI
- Legal : Willkie Farr Gallagher – C. GARAUD / V. SAYAG
- Finance : Deloitte – T. FISCHER
- Tax and Social : Bureau Francis Lefebvre – P. GOSSET / V. DELAGE
About Ekkio Capital
Ekkio Capital is an independent private equity firm funded by institutional investors, regulated by the French AMF (Autorité des marchés financiers) and investing for more than 15 years in high potential growth French and European SMEs. Specialising in Tourism & Leisure, Health care and TIC (Testing, Inspection & Certification), Ekkio Capital has today more than €230m under management and has successfully achieved 30 buy-out and development transactions.
Citigate Dewe Rogerson
01 53 32 78 92 / 07 60 90 89 12